{"id":"jk-1201i","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"JK-1201I activates glucagon-like peptide-1 (GLP-1) receptors, which enhance insulin secretion in response to glucose, slow gastric emptying, and promote satiety. As a long-acting formulation, it provides sustained therapeutic effects with less frequent dosing compared to shorter-acting GLP-1 agonists, making it suitable for chronic management of type 2 diabetes and obesity.","oneSentence":"JK-1201I is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:40.168Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management"}]},"trialDetails":[{"nctId":"NCT06595186","phase":"PHASE2","title":"JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)","status":"RECRUITING","sponsor":"JenKem Technology Co., Ltd.","startDate":"2022-10-31","conditions":"Glioblastoma Multiforme (GBM)","enrollment":25},{"nctId":"NCT06586866","phase":"PHASE2","title":"JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"JenKem Technology Co., Ltd.","startDate":"2024-09-26","conditions":"Triple Negative Breast Cancer (TNBC), Brain Metastasases","enrollment":25},{"nctId":"NCT04366648","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor","status":"COMPLETED","sponsor":"JenKem Technology Co., Ltd.","startDate":"2018-05-04","conditions":"Solid Tumor","enrollment":25},{"nctId":"NCT06581380","phase":"PHASE3","title":"JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"JenKem Technology Co., Ltd.","startDate":"2024-09-16","conditions":"Small Cell Lung Cancer","enrollment":394},{"nctId":"NCT05158491","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC","status":"UNKNOWN","sponsor":"JenKem Technology Co., Ltd.","startDate":"2021-11-11","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":63}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PEG-Irinotecan"],"phase":"phase_3","status":"active","brandName":"JK-1201I","genericName":"JK-1201I","companyName":"JenKem Technology Co., Ltd.","companyId":"jenkem-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JK-1201I is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. Used for Type 2 diabetes mellitus, Obesity or weight management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}